7.15
7.15 (0%)
As of Sep 17, 2024
G1 Therapeutics, Inc. [GTHX]
Source:
Company Overview
G1 Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel small molecule therapeutics for the treatment of patients with cancer.
| Country | United States |
| Headquarters | research triangle park, north carolina |
| Phone Number | (919) 213-9835 |
| Industry | manufacturing |
| CEO | John E. Bailey, Jr. |
| Website | www.g1therapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $16.5 |
| Operating Profit | $-3.5 |
| Net Income | $-5.5 |
| Net Cash | $-17.1 |
Profit Ratios
| Gross Margin | $15.8 |
| Operating Margin | -21.4 |
| Profit as % of Revenues | -289.1% |
| Profit as % of Assets | -9.5% |
| Profit as % of Stockholder Equity | -22.2% |
Management Effectiveness
| Return on Equity | -22.2% |
| Return on Assets | -5.5% |
| Turnover Ratio | 28.7% |
| EBITA | $-3.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $98.7 |
| Total Liabilities | $74.1 |
| Operating Cash Flow | $-14.2 |
| Investing Cash Flow | $5.5 |
| Financing Cash Flow | $-8.5 |
